United Therapeutics Corporation (UTHR)

業務介紹

聯合治療公司是一家生物科技公司，致力於開發和商業化產品，以滿足美國和國際上患有慢性和危及生命疾病的患者的醫療需求。其商業療法包括Remodulin，用於治療肺動脈高壓症（PAH）患者以減輕與運動相關的症狀；Tyvaso，一種吸入型前列腺素類似物曲前列醇，可增強PAH患者和與間質性肺疾病（PH-ILD）相關的肺動脈高壓患者的運動能力；Orenitram，一種曲前列醇片劑，可增強PAH患者的運動能力；Unituxin，一種用於治療高風險神經母細胞瘤的單克隆抗體；以及Adcirca，一種口服PDE-5抑制劑，可增強PAH患者的運動能力。該公司還致力於開發Tyvaso DPI，一種Tyvaso的乾粉吸入劑形式；Remunity泵，一種小型、輕便、耐用的泵和獨立控制器；RemoPro和Ralinepag，用於治療PAH；Aurora-GT，一種基因治療產品，用於重建肺部血管；以及Tyvaso PERFECT和TETON研究，這些研究是針對患有世界衛生組織（WHO）第3組與慢性阻塞性肺疾病（PH-COPD）相關的肺動脈高壓的Tyvaso的研究。該公司與DEKA研究和開發公司簽訂了許可和合作協議，以開發用於皮下給藥的半一次性系統；與MannKind Corporation簽訂了開發和許可曲前列醇吸入粉劑和Dreamboat設備的協議；以及與Arena Pharmaceuticals, Inc.簽訂了開發Ralinepag的協議。該公司成立於1996年，總部位於馬里蘭州銀泉市。

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

公司網址

https://www.unither.com